BeiGene, Ltd. (BGNE) Social Stream



BeiGene, Ltd. (BGNE): $194.48

27.53 (+16.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BGNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

BeiGene Ltd (BGNE) Price Targets From Analysts

Use the tables below to see what analysts covering BeiGene Ltd think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 5 $431 $343.3 $403.716 $216.05 86.86%
2022-01-06 6 $431 $283.3 $392.46 $216.05 81.65%
2022-01-12 6 $431 $283.3 $388.716 $216.05 79.92%
2022-01-18 6 $431 $283.3 $380.883 $216.05 76.29%
2022-01-28 6 $431 $283.3 $367.55 $216.05 70.12%
2022-02-08 6 $431 $283.3 $354.216 $216.05 63.95%
2022-02-25 6 $431 $283.3 $348.55 $216.05 61.33%
2022-02-28 6 $431 $254 $332.333 $216.05 53.82%
2022-03-17 6 $431 $177 $311.833 $216.05 44.33%

The Trend in the Analyst Price Target


Over the past 20 months, BGNE's average price target has gone up $85.65.

Over the past 129 days, BGNE's average upside potential has been 44.44%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-08 6 431 343.3 403.716 349.84 15.4%
2022-01-12 6 431 283.3 388.716 249.69 55.68%
2022-01-18 6 431 283.3 380.883 239.63 58.95%
2022-02-25 6 431 283.3 348.550 214.11 62.79%
2022-03-17 6 431 177.0 300.200 189.04 58.8%

BGNE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.75 3 1 2 0 0 6

The Trend in the Broker Recommendations


BGNE's average broker recommendation rating worsened by 0.26 over the prior 24 months.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, BeiGene Ltd's average analyst price target is greater than 1249.92% of them.
  • To contextualize these metrics, consider that out of stocks in the large market cap category, BeiGene Ltd's number of analysts covering the stock is greater than 141.9% of them.
  • BGNE has a greater upside potential (average analyst target price relative to current price) than 1106.9% of stocks in the large market cap category.
  • In terms of how BeiGene Ltd fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -346.72% of that group.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to BeiGene Ltd are BAYRY, AZN, and ALNY.

Make investment decisions regarding BGNE using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.479 seconds.